ToF-studie Embryo transfer, day Three Or day Five, in good prognosis IVF cycles.

Cumulative live birth rate after cleavage-stage(day three) or blastocyst(day five) stage embryo transfer in good prognosis IVF/ICSI cycles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON23649

Enrollment

1200

Registered

2018-02-19

Start date

2018-04-01

Completion date

Unknown

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Embryotransfer Day 3 vs Day 5 In Vitro Fertilization(IVF) Cumulative live birth rate Embryotransfer Dag 3 vs Dag 5 In Vitro Fertilisatie(IVF) Cumulatief aantal levend geborenen

Interventions

Blastocyst stage (day 5) embryo transfer

Eligibility

Inclusion criteria

Inclusion criteria: Women 18-42 years IVF/ICSI treatment with more than 3 zygotes on culture day 1 available. Written informed consent

Exclusion criteria

Exclusion criteria: The use of testicular sperm extraction (TESE), Preimplantation genetic diagnosis (PGD)cycles The use of vitrified oocytes -Participating in interfering study.

Design outcomes

Primary

Measure	Time frame
The primary aim is to study whether blastocyst stage embryo transfers (day 5) improves the cumulative LBR in IVF/ ICSI patients with a good prognosis (> 3 zygotes on day 1 after oocyte retrieval).	—

Secondary

Measure	Time frame
1.) Parameters of IVF treatment: such as live birth rate per first transfer, time to pregnancy, cumulative live birth rate (> 24 weeks) per started IVF/ICSI cycle, implantation rate, miscarriage rate. 2.) Parameters of perinatal treatment: i.e. birth defects, perinatal mortality, preterm birth ( 4kg), small for gestational age ( 90th percentile or > + 2SD), placenta previa, placental abruption, placenta accreta, pregnancy-induced hypertension, preeclampsia/ HELLP, gestational diabetes mellitus, placental abruption, preterm rupture of membranes, postpartum hemorrhage, caesarean section, Apgar < 7 at 5 min, stillbirth per ongoing pregnancy. 3.) Patient outcome analysis: Quality-Adjusted Life-Years (EuroQol (EQ-5D-5L) and the Fertility Quality of Life Questionnaire (FertiQoL)). 4.) A cost-effectiveness analysis (CEA) will be performed from a healthcare perspective. A cost-utility analysis (CUA) will be performed to relate the burden of intervention to the transfer strategy	—

Measure

Time frame

1.) Parameters of IVF treatment: such as live birth rate per first transfer, time to pregnancy, cumulative live birth rate (> 24 weeks) per started IVF/ICSI cycle, implantation rate, miscarriage rate. 2.) Parameters of perinatal treatment: i.e. birth defects, perinatal mortality, preterm birth ( 4kg), small for gestational age ( 90th percentile or > + 2SD), placenta previa, placental abruption, placenta accreta, pregnancy-induced hypertension, preeclampsia/ HELLP, gestational diabetes mellitus, placental abruption, preterm rupture of membranes, postpartum hemorrhage, caesarean section, Apgar < 7 at 5 min, stillbirth per ongoing pregnancy. 3.) Patient outcome analysis: Quality-Adjusted Life-Years (EuroQol (EQ-5D-5L) and the Fertility Quality of Life Questionnaire (FertiQoL)). 4.) A cost-effectiveness analysis (CEA) will be performed from a healthcare perspective. A cost-utility analysis (CUA) will be performed to relate the burden of intervention to the transfer strategy

—

Contacts

Public ContactSimone Cornelisse

RadboudUMC, Voortplantinggeneeskunde

tof@zorgevaluatienederland.nl024 361 6644

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)